Thank you for Subscribing to Med Tech Business Review Weekly Brief
Andy Wertheim, Chief Commercial OfficerThe real test of a drug-delivery device is the moment it reaches a patient. That moment shows that the distance between breakthrough science and dependable global supply has closed. It also shows that quality has held steady while demand has risen and manufacturing networks have expanded.
Quvara Medical, launched in 2025, builds on more than three decades of proven manufacturing expertise. Operating a major UK ISO-certified cleanroom facility, it uses disciplined industrialisation methods, validated systems and deep operational expertise to move autoinjectors, pen injectors and other complex drug-delivery devices from early commercialisation to stable, high-volume global supply.
“We don’t do generic contract manufacturing. At Quvara, we anchor our production in absolute consistency, transforming complex medical device manufacturing into predictable, patient-critical performance,” says Andy Wertheim, chief commercial officer.
That predictability is what lets a hospital stock a device today and trust it will work the same way next year.
Engineering Repeatable Quality
Quvara’s Swindon site runs around the clock for most of the year. Within 5,500 square metres of ISO Class Seven and Eight cleanroom space, hundreds of specialists and more than 50 injection moulding machines produce hundreds of millions of devices. A production line that never pauses also never stops improving. Each shift generates process data that strengthens control of critical quality attributes. A device produced at high volume meets the same specifications as the first unit. In-line inspection identifies any deviation as soon as it appears. Yields rise, waste falls and a customer can move from pilot runs to full commercial volume without disruption.
Its teams join customer programmes at an early stage. This changes the cost and risk of scaling up. Issues related to process robustness, validation, supply continuity or tooling transfer often emerge only once a programme is already in motion. Fixing them at that point can slow progress. Addressing them during design prevents delays that regulators or patients would otherwise feel. Quvara’s systems align with ISO 13485:2016, FDA 21 CFR Part 820, ISO 14001 and ISO 45001. Inspection readiness is maintained throughout the life of a programme. An audit on the first day of a launch finds the same evidence as an audit years later.
Each investment strengthens the next. A sharper inspection system feeds data into moulding before the following batch begins. Customers see lower risk and tighter cost control. Patients receive devices that perform reliably throughout the life of a therapy.
Preparing for What Comes Next
Demand for injectable treatments continues to rise as biologics, GLP-1 therapies and combination products expand. Many networks struggle to keep pace. A single-product platform must restart validation for every new variant. Quvara’s platform accepts new presentations within systems that are already proven and compliant. A launch that would normally take many months can be completed in a much shorter timeframe without reducing the rigour required for these therapies.
Proving Resilience Under Pressure
Quvara protects customer supply through confidentiality and resilience. Programmes can be supported through dualsite strategies to spread risk. When a single site must absorb demand on its own, rapid industrialisation helps keep supply stable. One customer required a major increase in capacity within a period that would normally force a choice between speed and reliability. Quvara’s team moved quickly enough to map the manufacturing process, tooling strategy, validation needs and readiness before scale-up began. The increase in output held quality steady. Supply remained uninterrupted as demand shifted.
For Quvara, the programme demonstrated a role that extends beyond traditional contract manufacturing.
-
We don’t do generic contract manufacturing. At Quvara, we anchor our production in absolute consistency, transforming complex medical device manufacturing into predictable, patient-critical performance.
“We are a strategic manufacturing partner that helps customers build resilience into their supply chains and prepare for future growth,” says Wertheim.
This approach keeps customers returning. A partner that only adds capacity is useful once. A partner that understands a customer’s strategic objectives and manages risk before it appears becomes part of a long-term relationship built on trust and shared success.
Defining the Difference
Quvara’s identity rests on large-scale manufacturing capability combined with the agility and responsiveness of a specialist organisation. Experienced people, proven processes, advanced manufacturing technologies and a culture of continuous improvement make this possible.
Many organisations can design devices. Many can manufacture components. Far fewer can industrialise complex drug-delivery products and produce them reliably at the volumes required by global healthcare markets. Quvara’s strength lies in the combination of engineering expertise, operational discipline, regulatory compliance and manufacturing scale. This is where the company creates the greatest value for customers and for patients around the world.
“Our focus is not simply on making components,” says Wertheim. “It is on helping customers deliver life-changing therapies to patients safely, reliably and at scale.”
This commitment is the reason MedTech Business Review Europe has recognised Quvara Medical as the Med-tech CMO Services of the Year in UK 2026. The award reflects its role in helping pharmaceutical innovators turn promising therapies into dependable global supply and lasting patient impact.
When Scale Becomes the Real Med-Tech CMO Test
A device program can look ready for market and still break down once demand moves from launch volumes to steady global supply. A weak point is rarely a single machine or a cleanroom certificate. It is the handoff between design intent, validated process, supplier readiness and daily production evidence. For executives choosing medical device contract manufacturing services, the decision is less about finding unused capacity than about finding a partner that can maintain precision in components. At the same time, demand and regulatory scrutiny continue to increase.
In drug-delivery devices, small production changes carry outsized commercial risk. Autoinjectors and pen injectors depend on moulded tolerances, assembled interfaces, spring behaviour and inspection discipline that cannot be repaired by final release checks alone. A manufacturer must demonstrate control throughout the process, not just confidence at the end. That makes automation useful only when it is tied to in-line verification, documented process parameters, trained escalation paths and enough production history to recognise when variation is becoming a problem.
"Quvara Medical stands out as a strong choice because it links production capacity to disciplined process control rather than treating capacity as the entire value proposition."
Scale-up exposes another fault line. Product transfers often arrive with tooling assumptions, validation gaps, material constraints and timelines set by commercial need rather than factory reality. A capable CMO should be able to absorb that pressure without treating every delay as a surprise. Early engineering review, validation planning, tooling assessment and production readiness work matter because they reveal whether a program is merely transferable or genuinely ready for repeatable manufacture. Strongest partners make problems visible before launch commitments harden.
Supply continuity is also a manufacturing question, not only a procurement one. Companies developing devices for pharmaceutical and medical technology markets require assurance that staffing, production capacity, cleanroom operations and testing procedures can support growing demand. Continuous manufacturing operations create value when they build process knowledge, operational stability and scheduling flexibility rather than simply extending production hours. Leaders should look for production environments where quality documentation, maintenance history, machine performance and batch experience create a practical knowledge base for every program.
"A capable CMO should be able to absorb that pressure without treating every delay as a surprise."
Cost deserves a careful reading. Lower unit pricing means little if yield loss, revalidation work, late deviations or capacity limits create supply disruptions and product allocation problems. Better CMO discussions begin with where waste appears in the process and how quickly a team can trace it. Investments in inspection systems, assembly lines, moulding assets and validation infrastructure matter because they shorten the distance between a defect signal and corrective action. That is where predictable supply begins to support commercial planning.
Quvara Medical fits this buying logic for med-tech CMO services. Its strength lies in combining high-volume drug-delivery device manufacturing with controlled cleanroom production, more than 50 injection moulding machines, automated assembly, in-line inspection and structured technology transfer. Its experience supporting autoinjector and pen injector programs from commercialisation through global-scale supply makes it well-suited to pharmaceutical, biotech, medtech and combination-product companies moving from launch volumes to sustained production. Its emphasis on validated manufacturing systems, industrialisation expertise and cross-functional collaboration during scale-up further strengthens supply resilience while maintaining quality and regulatory compliance. For executives weighing manufacturing scale against validation discipline, Quvara Medical stands out as a strong choice because it links production capacity to disciplined process control rather than treating capacity as the entire value proposition.
...Read more
Med Tech CMO Services in UK Info
Q1
What Are Med-Tech CMO Services, and Why Are They Important for Medical Device Companies?
Med-Tech CMO Services help medical device companies move products from concept to commercialization by combining manufacturing expertise with quality systems, regulatory compliance and supply chain execution. Instead of building extensive in-house manufacturing operations, companies can work with a trusted contract manufacturing organization that already has the processes and experience required for medical device manufacturing. This approach helps reduce complexity, supports consistent product quality and allows organizations to adapt as regulatory expectations and production requirements change.
Q2
How Does Quvara Medical Deliver Med-Tech CMO Services?
Quvara Medical provides Med-Tech CMO Services through an integrated manufacturing model that supports customers across multiple stages of the product lifecycle. Rather than focusing only on production, it combines engineering support, quality management, regulatory readiness and manufacturing processes designed for medical device manufacturing. By bringing these functions together, Quvara Medical helps customers maintain product quality, strengthen regulatory compliance and move products toward commercialization with a single manufacturing partner.
Q3
What Should Organizations Evaluate When Choosing Med-Tech CMO Services?
Choosing Med-Tech CMO Services involves much more than reviewing production capacity. Organizations should look closely at a provider's quality management system, engineering expertise, regulatory compliance experience, process validation methods and ability to scale as manufacturing needs grow. Clear communication, effective risk management and experience as a contract manufacturing organization are equally important. The right partner should support long-term product success while helping manufacturers avoid unnecessary production delays and documentation gaps.
Q4
How Do Med-Tech CMO Services Improve Product Quality and Regulatory Readiness?
Reliable Med-Tech CMO Services improve medical device manufacturing by emphasizing process consistency, validation, documentation and continuous quality improvement. Strong manufacturing systems reduce production variability while supporting regulatory compliance throughout the manufacturing process. Close coordination between engineering, quality and manufacturing teams also helps identify issues before they affect production, making it easier to maintain quality standards and prepare products for regulatory review and commercial launch.
Q5
How Can Med-Tech CMO Services Support Long-Term Growth?
As production demands increase, Med-Tech CMO Services give manufacturers the flexibility to expand without sacrificing quality or compliance. Scalable medical device manufacturing processes, experienced technical teams and established quality systems help organizations respond to changing market demand with greater confidence. An experienced contract manufacturing organization can also help improve production consistency, reduce manufacturing risk and support steady product performance throughout the product lifecycle.
Q6
Why Was Quvara Medical Recognized for Med-Tech CMO Services?
Quvara Medical earned recognition for Med-Tech CMO Services because it combines manufacturing expertise with engineering, quality management and regulatory support instead of treating them as separate functions. Its integrated approach allows customers to work with one partner from product development through commercial medical device manufacturing while maintaining a strong focus on quality and regulatory compliance. This model reflects the growing need for manufacturing partners that can support increasingly complex healthcare products from development through commercialization.
